ANIX Stock Overview
Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Anixa Biosciences, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$3.18 |
| 52 Week High | US$5.13 |
| 52 Week Low | US$2.75 |
| Beta | 0.87 |
| 1 Month Change | -1.55% |
| 3 Month Change | -29.80% |
| 1 Year Change | -25.18% |
| 3 Year Change | -34.97% |
| 5 Year Change | -28.22% |
| Change since IPO | -93.48% |
Recent News & Updates
Recent updates
We're Not Worried About Anixa Biosciences' (NASDAQ:ANIX) Cash Burn
Jan 19
We Think Anixa Biosciences (NASDAQ:ANIX) Can Easily Afford To Drive Business Growth
Oct 06Is There An Opportunity With Anixa Biosciences, Inc.'s (NASDAQ:ANIX) 41% Undervaluation?
Apr 27Are Investors Undervaluing Anixa Biosciences, Inc. (NASDAQ:ANIX) By 36%?
Jan 13We're Interested To See How Anixa Biosciences (NASDAQ:ANIX) Uses Its Cash Hoard To Grow
Sep 26Anixa adds 11% after dosing initiation in CAR-T ovarian cancer trial
Aug 15Anixa to get additional US patent linked to breast cancer vaccine technology
Jul 21Anixa Biosciences (NASDAQ:ANIX) Is In A Good Position To Deliver On Growth Plans
Jun 13Anixa: Making Sense Of A Bullish Move Up In Bearish Biotech Times
May 11We're Interested To See How Anixa Biosciences (NASDAQ:ANIX) Uses Its Cash Hoard To Grow
Feb 24Companies Like Anixa Biosciences (NASDAQ:ANIX) Can Afford To Invest In Growth
Oct 28Our First Look At Anixa Biosciences
Sep 23Here's Why We're Not At All Concerned With Anixa Biosciences' (NASDAQ:ANIX) Cash Burn Situation
Jun 12OntoChem assigns Anixa covid-19 drug discovery project to MolGenie
May 07Anixa Biosciences (NASDAQ:ANIX) Is In A Good Position To Deliver On Growth Plans
Jan 13
Anixa Biosciences, Cleveland Clinic in ovarian cancer vaccine pact
Dec 01Shareholder Returns
| ANIX | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 4.3% | 1.0% | 1.2% |
| 1Y | -25.2% | 0.7% | 24.9% |
Price Volatility
| ANIX volatility | |
|---|---|
| ANIX Average Weekly Movement | 9.2% |
| Biotechs Industry Average Movement | 11.6% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: ANIX's share price has been volatile over the past 3 months.
Volatility Over Time: ANIX's weekly volatility (9%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1982 | 5 | Amit Kumar | www.anixa.com |
Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company’s therapeutics programs include the development of a chimeric endocrine receptor T-cell therapy, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer. Its vaccine programs comprise the development of a vaccine against triple negative breast cancer; and a preventative vaccine against ovarian cancer.
Anixa Biosciences, Inc. Fundamentals Summary
| ANIX fundamental statistics | |
|---|---|
| Market cap | US$97.93m |
| Earnings (TTM) | -US$10.74m |
| Revenue (TTM) | US$210.00k |
483.1x
P/S Ratio-9.4x
P/E RatioIs ANIX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ANIX income statement (TTM) | |
|---|---|
| Revenue | US$210.00k |
| Cost of Revenue | US$161.00k |
| Gross Profit | US$49.00k |
| Other Expenses | US$10.79m |
| Earnings | -US$10.74m |
Last Reported Earnings
Jan 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.34 |
| Gross Margin | 23.33% |
| Net Profit Margin | -5,116.19% |
| Debt/Equity Ratio | 0% |
How did ANIX perform over the long term?
See historical performance and comparison